Contribute Try STAT+ Today

The coronavirus pandemic has thrown a wrench into plans for hundreds of clinical trials seeking therapies for diseases beyond Covid-19. But some investigators and sponsors are trying to push ahead, tailoring ways to keep patients enrolled while keeping them safe and to ensure the trial can still produce rigorous evidence of whether or not a drug works.

“The problem that we all want to avoid is that despite our best efforts, the results from a given clinical trial will turn out to be so incomplete or unreliable as to make them uninterpretable,” Pfizer chief medical officer Mace Rothenberg said during a webinar last week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy